GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>The nearest catalyst for GTCB is rates for reimbursement in EU countries which might give better insight into revenues down the road.<

I think it’s a mistake to consider the HD indication in Europe as more than a proof of concept for the platform. Revenues for GTC from this program in 2007 and 2008 are not going to be enough to affect the bottom line greatly.

Much bigger catalysts will be: 1) The reporting of top-line data from the US ATryn trial, which will happen in a few months; and 2) Inking a US ATryn partnership, which could happen at any time. Regards, Dew